Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model

American Journal of Pathology

Volumn 178, Issue 3, 2011, Pages 1298-1308

  Cui, Yujie ^a   Huang, Mingwei ^a   He, Yingbo ^a   Zhang, Shuyan ^a   Luo, Yongzhang ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN A4; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DISEASE COURSE; LEARNING DISORDER; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 79952763970     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.11.057     Document Type: Article

References (57)

1. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356 (Pubitemid 34790756)
2. Selkoe D, Kopan R: Notch and presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 2003, 26:565-597 (Pubitemid 37064944)
3. Zheng H, Koo EH: The amyloid precursor protein: beyond amyloid. Mol Neurodeg 2006, 1:5
4. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M: Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741
5. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, Annaert W, Von Figura K, Van Leuven F: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998, 391:387-390 (Pubitemid 28093512)
6. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999, 398:513-517
7. Hatten ME, Liem RK, Shelanski ML, Mason CA: Astroglia in CNS injury. Glia 1991, 4:233-243
8. Montgomery DL: Astrocytes: form, functions, and roles in disease. Vet Pathol 1994, 31:145-167
9. Shao Y, McCarthy KD: Plasticity of astrocytes. Glia 1994, 11:147-155 (Pubitemid 2116310)
10. al-Ali SY, al-Hussain SM: An ultrastructural study of the phagocytic activity of astrocytes in adult rat brain. J Anat 1996, 188 (Pt 2):257-262
11. Guillaume D, Bertrand P, Dea D, Davignon J, Poirier J: Apolipoprotein E and low-density lipoprotein binding and internalization in primary cultures of rat astrocytes: isoform-specific alterations. J Neurochem 1996, 66:2410-2418 (Pubitemid 26159076)
12. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC, Husemann J: Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003, 9:453-457 (Pubitemid 36460080)
13. Wegiel J, Wang KC, Tarnawski M, Lach B: Microglia cells are the driving force in fibrillar plaque formation, whereas astrocytes are a leading factor in plague degradation. Acta Neuropathol 2000, 100:356-364 (Pubitemid 30497003)
14. Koudinov A, Matsubara E, Frangione B, Ghiso J: The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem Biophys Res Commun 1994, 205:1164-1171
15. Koudinov AR, Koudinova NV, Kumar A, Beavis RC, Ghiso J: Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun 1996, 223:592-597 (Pubitemid 26246118)
16. Koudinov AR, Berezov TT, Kumar A, Koudinova NV: Alzheimer's amyloid beta interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta 1998, 270:75-84 (Pubitemid 28095681)
17. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993, 90:1977-1981 (Pubitemid 23069980)
18. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923 (Pubitemid 23275809)
19. Fagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, Getz GS, Reardon CA, Lukens J, Shah JA, LaDu MJ: Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J Biol Chem 1999, 274:30001-30007
20. Kim J, Basak JM, Holtzman DM: The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303
21. Ma J, Yee A, Brewer HB Jr, Das S, Potter H: Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994, 372:92-94
22. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B: Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 1994, 145:1030-1035 (Pubitemid 24345650)
23. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM: Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997, 17:263-264
24. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM: Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 1999, 96:15233-15238 (Pubitemid 30019795)
25. Beffert U, Poirier J: ApoE associated with lipid has a reduced capacity to inhibit beta-amyloid fibril formation. Neuroreport 1998, 9:3321-3323 (Pubitemid 28522355)
26. Wood SJ, Chan W, Wetzel R: Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 1996, 35:12623-12628 (Pubitemid 26318060)
27. DeMattos RB, O'Dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM: Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2002, 99:10843-10848
28. Fagan AM, Christopher E, Taylor JW, Parsadanian M, Spinner M, Watson M, Fryer JD, Wahrle S, Bales KR, Paul SM, Holtzman DM: ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am J Pathol 2004, 165:1413-1422 (Pubitemid 39297745)
29. Beisiegel U, Utermann G: An apolipoprotein homolog of rat apolipoprotein A-IV in human plasma. Isolation and partial characterization. Eur J Biochem 1979, 93:601-608 (Pubitemid 9218159)
30. Weinberg RB, Scanu AM: Isolation and characterization of human apolipoprotein A-IV from lipoprotein-depleted serum. J Lipid Res 1983, 24:52-59 (Pubitemid 13146777)
31. Goldberg IJ, Scheraldi CA, Yacoub LK, Saxena U, Bisgaier CL: Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem 1990, 265:4266-4272
32. Sato K, Takahashi Y, Takahashi T, Katoh N, Akiba Y: Identification of factors regulating lipoprotein lipase catalyzed hydrolysis in rats with the aid of monoacid-rich lipoprotein preparations(1). J Nutr Biochem 2002, 13:528
33. Vowinkel T, Mori M, Krieglstein CF, Russell J, Saijo F, Bharwani S, Turnage RH, Davidson WS, Tso P, Granger DN, Kalogeris TJ: Apolipoprotein A-IV inhibits experimental colitis. J Clin Invest 2004, 114:260-269 (Pubitemid 39071631)
34. Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P: Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol 1998, 274:H1836-H1840
35. Bergstrom J, Murphy C, Eulitz M, Weiss DT, Westermark GT, Solomon A, Westermark P: Codeposition of apolipoprotein A-IV and transthyretin in senile systemic (ATTR) amyloidosis. Biochem Biophys Res Commun 2001, 285:903-908 (Pubitemid 32918021)
36. Bergstrom J, Murphy CL, Weiss DT, Solomon A, Sletten K, Hellman U, Westermark P: Two different types of amyloid deposits-apolipoprotein A-IV and transthyretin-in a patient with systemic amyloidosis. Lab Invest 2004, 84:981-988 (Pubitemid 39025033)
37. Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC, Steinmetz A, Denefle P: Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996, 273:966-968 (Pubitemid 26275175)
38. Fujimoto K, Cardelli JA, Tso P: Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol 1992, 262:G1002-G1006
39. Fujimoto K, Fukagawa K, Sakata T, Tso P: Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J Clin Invest 1993, 91:1830-1833 (Pubitemid 23127391)
40. Csaszar A, Kalman J, Szalai C, Janka Z, Romics L: Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease. Neurosci Lett 1997, 230:151-154 (Pubitemid 27342188)
41. Merched A, Xia Y, Papadopoulou A, Siest G, Visvikis S: Apolipoprotein AIV codon 360 mutation increases with human aging and is not associated with Alzheimer's disease. Neurosci Lett 1998, 242:117-119 (Pubitemid 28083006)
42. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R: Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006, 26:10129-10140 (Pubitemid 44527407)
43. Vorhees CV, Williams MT: Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006, 1:848-858
44. Schmidt SD, Jiang Y, Nixon RA, Mathews PM: Tissue processing prior to protein analysis and amyloid-beta quantitation. Methods Mol Biol 2005, 299:267-278
45. Pearson K, Saito H, Woods SC, Lund-Katz S, Tso P, Phillips MC, Davidson WS: Structure of human apolipoprotein A-IV: a distinct domain architecture among exchangeable apolipoproteins with potential functional implications. Biochemistry 2004, 43:10719-10729
46. Murphy BF, Kirszbaum L, Walker ID, d'Apice AJ: SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J Clin Invest 1988, 81:1858-1864
47. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, Frosch MP, Selkoe DJ: Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093 (Pubitemid 38032786)
48. Ganguli M, Dodge HH, Shen CY, Pandav RS, DeKosky ST: Alzheimer disease and mortality: a 15-year epidemiological study. Arch Neurol 2005, 62:779-784 (Pubitemid 40656094)
49. Matsubara E, Frangione B, Ghiso J: Characterization of apolipoprotein J-Alzheimer's A beta interaction. J Biol Chem 1995, 270:7563-7567
50. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE: ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693 (Pubitemid 351778466)
51. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ: Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 1996, 271:32916-32922 (Pubitemid 27008725)
52. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, Abramowski D, Sturchler-Pierrat C, Sommer B, Staufenbiel M, Jucker M: Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A 1999, 96:14088-14093
53. Van Dorpe J, Smeijers L, Dewachter I, Nuyens D, Spittaels K, Van Den Haute C, Mercken M, Moechars D, Laenen I, Kuiperi C, Bruynseels K, Tesseur I, Loos R, Vanderstichele H, Checler F, Sciot R, Van Leuven F: Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am J Pathol 2000, 157:1283-1298
54. Liu M, Doi T, Shen L, Woods SC, Seeley RJ, Zheng S, Jackman A, Tso P: Intestinal satiety protein apolipoprotein AIV is synthesized and regulated in rat hypothalamus. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1382-R1387
55. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM: Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004, 10:719-726 (Pubitemid 38937637)
56. Bisgaier CL, Sachdev OP, Megna L, Glickman RM: Distribution of apolipoprotein A-IV in human plasma. J Lipid Res 1985, 26:11-25 (Pubitemid 15133290)
57. Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, Hansen JC, Sullivan PM, Paul SM: Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 2009, 29:6771-6779